Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition
Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Cyclooxygenase-2 (COX-2) inhibitors have become a common analgesic treatment option for
patients with arthritis. However, long-term treatment has been associated with increased
cardiovascular risk. With the past withdrawals and rejections of approval for COX-2
inhibitors the treatment options are now very limited.
This translates for example to about 10 million osteoarthritis patients in the US who cannot
receive COX-2 inhibitors because of concomitant hypertension. And this exemplifies the unmet
medical need to develop and offer safe treatment options for this particular patient
population.
This trial investigates pharmacodynamic aspects of CG100649 which is being developed as a
novel COX-2 inhibitor. Preclinical data show a dual mechanism of action, which consists of
the inhibition of the two enzymes COX-2 and carbonic anhydrase-I/-II (CA-I/II) and through
which the cardiovascular risk of COX-2 inhibition might be attenuated.